생검 겸자 시장 : 제품 유형, 용도, 최종 사용자, 유통 채널별 - 세계 예측(2026-2032년)

The Biopsy Forceps Market was valued at USD 234.78 million in 2025 and is projected to grow to USD 249.36 million in 2026, with a CAGR of 6.20%, reaching USD 357.78 million by 2032.

A concise clinical and operational overview of biopsy forceps reflecting the intersection of procedural demands, device design evolution, and sterilization priorities influencing adoption

Biopsy forceps are fundamental instruments within diagnostic endoscopy, enabling tissue sampling across pulmonary, gastrointestinal, gynecological, and urological procedures. Recent clinical trends have elevated the role of biopsy tools as precision accessories that materially influence diagnostic yield, procedure time, and downstream therapeutic decisions. As clinicians prioritize minimally invasive pathways, the demand for instruments that balance maneuverability, tactile feedback, and consistent sample quality has intensified. This dynamic is shaping product development cycles, regulatory attention, and hospital procurement criteria in parallel.

Technological refinement has progressed along multiple vectors: materials science focused on corrosion resistance and tip sharpness; ergonomic handle designs to reduce clinician fatigue; and manufacturing tolerances that ensure reproducible bite size within narrow anatomical corridors. Concurrently, infection prevention imperatives and sterilization workflows are driving divergent adoption patterns between reusable and single-use products. These operational and clinical drivers intersect with shifting procurement strategies, where value assessments increasingly weigh total cost of ownership, reprocessing logistics, and risk mitigation alongside unit price. The investment case for a biopsy forceps strategy therefore requires synthesis of clinical utility, lifecycle economics, and supply reliability to inform purchasing and product development decisions.

How clinical practice evolution, sterilization imperatives, and manufacturing innovation are driving a fundamental reshaping of biopsy forceps development and procurement

The landscape for biopsy forceps is undergoing transformative shifts rooted in clinical practice changes, supply chain adaptation, and product innovation. One prominent change is the move toward single-use instruments in select clinical settings to reduce cross-contamination risk and simplify reprocessing workflows. This shift is accompanied by enhanced single-use designs that approach the performance of reusable alternatives while addressing sterility and logistics concerns. At the same time, reusable instruments continue to evolve with improved autoclavable materials and chemical sterilization compatibility, ensuring they remain viable where lifecycle economics and environmental considerations are prioritized.

Procedural advancements such as increased uptake of endobronchial ultrasound and refined gastrointestinal endoscopic techniques have raised expectations for forceps precision and access. Device makers are responding with optimized tip profiles, enhanced shaft flexibility, and compatibility with a broader array of endoscope channels. Beyond pure mechanical improvements, integration of digital process controls and traceability features for reprocessed instruments is becoming more common, enabling healthcare facilities to better manage compliance and inventory. The result is a market that rewards manufacturers who can deliver clinical performance, streamlined sterilization pathways, and resilient supply solutions, while payers and procurement teams increasingly evaluate product value through a broader operational lens.

An examination of how 2025 tariff reforms have reshaped sourcing strategies, procurement practices, and manufacturing footprint decisions for biopsy forceps stakeholders

The cumulative impact of United States tariff actions announced for 2025 has introduced measurable complexity into biopsy forceps procurement and global sourcing strategies. Tariff adjustments have prompted many manufacturers and health system buyers to re-evaluate supplier footprints, particularly for components and finished devices imported from regions subject to elevated duties. In response, some original equipment manufacturers have accelerated nearshoring and onshoring initiatives to preserve price stability, shorten lead times, and insulate supply lines from trade policy volatility. These shifts are not purely transactional; they carry implications for manufacturing quality systems, regulatory filings, and supplier qualification timelines.

Procurement teams have reacted by revising contract terms, increasing emphasis on total landed cost analysis, and seeking longer-term supply commitments to mitigate future tariff exposures. For distributors and hospital procurement departments, tariff-driven cost pressure has reinforced the importance of diversified supplier panels and strategic stockholding to smooth operational continuity. Additionally, tariff dynamics have stimulated discussions around product portfolio rationalization, where less differentiated items may be consolidated to reduce SKU complexity and import dependencies. Across the value chain, compliance functions have heightened focus on classification, country-of-origin documentation, and tariff engineering opportunities that legally optimize duty treatment without compromising safety or regulatory compliance. The overarching effect is a more deliberate, risk-aware sourcing posture that integrates trade policy considerations into clinical supply planning and product lifecycle decisions.

Deep segmentation analysis revealing how product sterilization pathways, procedural applications, care settings, and distribution networks determine competitive differentiation

Segmentation-driven insight reveals how product characteristics, clinical applications, user settings, and distribution pathways jointly influence strategic positioning within the biopsy forceps arena. Based on Product Type, market is studied across Reusable and Single Use. The Reusable is further studied across Autoclavable and Chemical Sterilization. The Single Use is further studied across Non Sterile and Sterile. These distinctions matter because sterilization modality, reprocessing throughput, and end-of-life handling all feed into purchasing criteria and clinical workflow compatibility. Autoclavable reusable instruments are often favored in high-volume centers with mature sterile processing capacity, whereas chemically sterilized reusables or single-use sterile items may better serve facilities with constrained reprocessing infrastructure.

Based on Application, market is studied across Bronchoscopy, Gastrointestinal Endoscopy, Gynecology, and Urology. The Bronchoscopy is further studied across Conventional and Endobronchial Ultrasound. The Gastrointestinal Endoscopy is further studied across Colonoscopy and Esophagogastroduodenoscopy. Application-specific requirements dictate instrument dimensions, bite geometry, and shaft flexibility. For example, endobronchial ultrasound probes require forceps that maintain performance within narrow working channels while delivering adequate tissue for molecular diagnostics. In gastrointestinal procedures, the need for reliable retrieval during colonoscopy or esophagogastroduodenoscopy drives different design trade-offs between grasp strength and maneuverability.

Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals. Each setting imposes unique operational constraints: ambulatory centers prioritize rapid turnover and simplified reprocessing, clinics may seek cost-effective single-use solutions for lower-volume procedures, and hospitals demand a balance of durability and broad procedural compatibility. Based on Distribution Channel, market is studied across Distributors, Hospital Procurement, and Online Retail. Distribution choice affects lead times, aftermarket support, training offerings, and pricing transparency. The interplay of these segmentation dimensions shapes how manufacturers prioritize R&D investment, channel partnerships, and customer support models to match clinical and operational needs.

A comparative regional perspective clarifying how procurement priorities, regulatory frameworks, and manufacturing capacity shape biopsy forceps adoption across global healthcare markets

Regional dynamics exert strong influence on clinical adoption, procurement behavior, and regulatory pathways for biopsy forceps, with distinct drivers observed in the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, emphasis on patient safety, infection control, and bundled procurement has supported exploration of single-use alternatives in specific procedure types, while large integrated delivery networks demand consistency, supplier reliability, and traceable reprocessing practices. Regulatory oversight tends to be rigorous, and reimbursement structures shape hospital-level adoption decisions and tender outcomes.

In Europe, Middle East & Africa, heterogeneous healthcare systems create a patchwork of adoption rates and procurement preferences. Western European markets often lead in innovation uptake and sustainability conversations, applying lifecycle cost assessments and environmental impact considerations to purchasing decisions. By contrast, other countries in the region may prioritize cost containment and supply chain availability, which can favor robust reusable portfolios. Regulatory harmonization efforts in some jurisdictions influence cross-border sourcing and clinical acceptance.

The Asia-Pacific region is characterized by rapid procedural volume growth, expanding access to endoscopic services, and increasing domestic manufacturing capability. Local production capacity is strengthening, driven by investment in precision manufacturing and competitive positioning for both regional and export markets. Across all regions, clinical education, distributor relationships, and regulatory alignment remain critical to translating product innovation into sustained utilization, and successful market entry strategies must be tailored to each regional ecosystem's procurement norms and clinical priorities.

Insights into competitive strategies showing how product innovation, regulatory readiness, and channel partnerships determine long-term differentiation and customer retention

Competitive dynamics among companies in the biopsy forceps space are defined by differentiated product portfolios, regulatory agility, and channel management. Leading firms are investing in manufacturing scalability, enhanced material sciences, and design refinements that deliver consistent tissue acquisition while meeting sterilization and reprocessing standards. Strategic partnerships with endoscope manufacturers and clinical centers are enabling iterative product improvements guided by real-world procedural feedback. In parallel, some players prioritize single-use platforms to address infection control concerns and simplify logistics for ambulatory environments.

Mergers, acquisitions, and distribution agreements continue to be mechanisms for accelerating market access and closing capability gaps, particularly in regions where local regulatory approvals and established distribution networks are critical. Companies that combine robust regulatory affairs capabilities with localized quality systems can shorten time-to-market for new SKUs. Aftermarket services such as clinician training, reprocessing support, and inventory management are increasingly material to competitive positioning, as buyers reward vendors who reduce operational friction. Manufacturers that focus on demonstrable clinical outcomes, rigorous validation studies, and responsive post-sale support are more likely to secure long-term procurement relationships in an environment where clinical performance and logistical reliability carry significant weight.

Actionable strategic priorities for manufacturers and procurement teams to enhance product performance, supply resilience, and commercial differentiation in clinical settings

Industry leaders should adopt a multi-pronged strategy that aligns product design, supply resilience, and customer-centric services to capture clinical preference and procurement trust. Prioritize development of forceps that deliver consistent tissue quality while minimizing additional workflow burden for sterile processing departments, and ensure that design choices reflect the sterilization modalities most prevalent among target end users. Simultaneously, expand single-use offerings where they provide clear infection prevention or workflow advantages, but maintain reusable options for high-volume centers that benefit from lifecycle economics.

Strengthen supply chain resilience by diversifying suppliers, qualifying alternative manufacturing sites, and considering nearshore production to mitigate tariff and logistics risks. Enhance commercial proposals with transparent total landed cost analyses and evidence packages that link device performance to procedural efficiency or diagnostic yield. Invest in clinician education programs and post-sale support to accelerate adoption and reduce procedural variability. Finally, adopt sustainability practices that address end-of-life handling and packaging optimization, recognizing that environmental considerations increasingly influence purchasing decisions across hospitals and health systems. A disciplined execution of these actions will help organizations balance short-term operational needs with long-term strategic positioning.

A transparent methodological exposition describing stakeholder interviews, secondary validation, and triangulation protocols used to derive strategic insights without quantitative estimations

The research underpinning this analysis combines primary qualitative engagement with stakeholders and rigorous secondary source triangulation to ensure a balanced, evidence-based perspective. Primary inputs included structured interviews with clinicians across pulmonology, gastroenterology, gynecology, and urology, in addition to dialogues with sterile processing managers, procurement professionals, and device engineers. These conversations provided granular insights into procedural needs, reprocessing constraints, and procurement decision criteria. Secondary inputs comprised regulatory filings, device instruction for use documentation, clinical procedure guides, and publicly available supplier announcements, which were used to validate themes emerging from primary research.

Data integrity was sustained through cross-verification across independent sources, coding of qualitative responses to identify recurring patterns, and assessment of regulatory and clinical documentation for consistency. Limitations are acknowledged: the research emphasized qualitative drivers and strategic dynamics rather than providing numerical market estimates; variations in regional clinical practice and procurement policies may generate different local outcomes. Ethical protocols were followed in all primary engagements, with interviewees participating on a non-attributable basis unless explicit permission was granted. The methodology is designed to be transparent and reproducible, offering a defensible foundation for the strategic conclusions and recommendations presented.

A decisive synthesis highlighting the practical imperatives for aligning device performance, sterilization workflows, and procurement strategy to support durable clinical adoption

In conclusion, biopsy forceps remain a pivotal class of instruments at the intersection of diagnostic precision and operational practicality. The balance between reusable and single-use solutions will continue to be negotiated across care settings as clinical priorities, sterilization infrastructure, and procurement frameworks evolve. Technology refinement in materials and ergonomics, coupled with heightened attention to infection prevention and supply resilience, creates opportunities for manufacturers that can deliver validated clinical performance alongside predictable lifecycle economics.

Successful market strategies will be those that integrate clinician-centered design, rigorous regulatory readiness, and supply chain flexibility to adapt to trade policy shifts and regional procurement norms. Providers and procurement teams must weigh clinical benefits against operational impacts and choose solutions that support consistent diagnostic outcomes while minimizing procedural and reprocessing burdens. The imperative is clear: align product development and commercial execution with the practical realities of clinical workflows and procurement constraints to secure sustained adoption and improve patient care pathways.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopsy Forceps Market, by Product Type

• 8.1. Reusable
  • 8.1.1. Autoclavable
  • 8.1.2. Chemical Sterilization
• 8.2. Single Use
  • 8.2.1. Non Sterile
  • 8.2.2. Sterile

9. Biopsy Forceps Market, by Application

• 9.1. Bronchoscopy
  • 9.1.1. Conventional
  • 9.1.2. Endobronchial Ultrasound
• 9.2. Gastrointestinal Endoscopy
  • 9.2.1. Colonoscopy
  • 9.2.2. Esophagogastroduodenoscopy
• 9.3. Gynecology
• 9.4. Urology

10. Biopsy Forceps Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Clinics
• 10.3. Hospitals

11. Biopsy Forceps Market, by Distribution Channel

• 11.1. Distributors
• 11.2. Hospital Procurement
• 11.3. Online Retail

12. Biopsy Forceps Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Biopsy Forceps Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Biopsy Forceps Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Biopsy Forceps Market

16. China Biopsy Forceps Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. ACE Medical Devices Pvt. Ltd.
• 17.6. Anrei medical (hz)co.,Ltd.
• 17.7. Argon Medical Devices
• 17.8. Becton, Dickinson and Company
• 17.9. Boston Scientific Corporation
• 17.10. Cardinal Health, Inc.
• 17.11. CONMED Corporation
• 17.12. Cook Group Incorporated
• 17.13. FUJIFILM Corporation
• 17.14. Integer Holdings Corporation
• 17.15. Integra LifeSciences Corporation
• 17.16. KARL STORZ SE & Co. KG
• 17.17. MedGyn Products, Inc.
• 17.18. Medi-Globe GmbH
• 17.19. Medline Industries, Inc.
• 17.20. Medorah Meditek Pvt. Ltd.
• 17.21. Medtronic PLC
• 17.22. MICRO-TECH (Nanjing) Co., Ltd,
• 17.23. Olympus Corporation
• 17.24. Omnimed Ltd.
• 17.25. PENTAX Medical by Hoya Corporation
• 17.26. Scanlan International, Inc.
• 17.27. Sklar Surgical Instruments
• 17.28. STERIS Corporation
• 17.29. Wilson Instruments (SHA) Co., Ltd.